Insiders Trades
Iradimed Corp Stock: price and insider trades · United States
Iradimed Corp: what insiders have been doing
Iradimed Corp, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 9 insiders have disclosed 65 filings since 18 October 2025.
The flow runs one way only: 52 sales worth €10.5M, from 4 insiders, and no purchase. At €1.2M, the sale published on 12 December 2025 by Glenn John is the largest of the period.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 65 filings, this issuer sits above that mark. Our records for Iradimed Corp go back to 2021, with no purchases and 150 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 83.8 m USD of revenue and 22.5 m USD of net income.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
204
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€37M
150 ops. · all time
Who traded when
BuySaleRoger E. Susi50 sales
Monty K. Allen4 sales
John Glenn3 sales
Hawkins James B2 sales
Vuoto Anthony1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,422 of 24,148 companies
61.2
score / 100
Value32
Quality90
FCF yld1.5%
Earn yld2.0%
EV/EBITDA41.3x
ROE24%
Gross mgn77%
Net mgn27%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$88.27
Analyst consensus
2 analysts1.67/5
US$116.00Target US$118.00(+34%)US$120.00
Income statement
RevenueUS$83.8M
Gross profitUS$64.3M77% margin
EBITDAUS$27.3M33% margin
Net incomeUS$22.5M26.7% margin
Valuation
PER (trailing)49.3x
PER (forward)36.0x
P/Book11.1x
Beta0.91
Balance sheet & cash
Market capUS$1.1B
Free Cash FlowUS$16.5M
Profitability & ownership
ROE23.5%
ROA15.6%
% insiders35.2%
% institutions62.5%
Last declaration on 25 September 2026
Declarations204 total
698 sharesCommon StockSEC:0001228621-26-000003:0
1,014 shares@ US$86.440.0078% mcap11.9% of flowCommon StockSEC:0001253352-26-000010:0
405 shares@ US$86.350.0031% mcap4.8% of flowCommon StockSEC:0001253352-26-000010:1
1,419 shares@ US$86.41610.011% mcap100.0% of flowCommon StockSEC144:0001253352-26-000008
5,796 sharesCommon StockSEC:0001253497-26-000005:0
2,319 sharesCommon StockSEC:0001253497-26-000005:1
3,000 shares@ US$95.00100.0% of flowCommon StockSEC144:0001950129-26-000004
2,819 shares@ US$88.980.019% mcap0.6% of flowCommon StockSEC:0001613801-26-000028:0
931 shares@ US$89.700.0063% mcap0.2% of flowCommon StockSEC:0001613801-26-000028:1
847 shares@ US$85.770.0055% mcap0.2% of flowCommon StockSEC:0001613801-26-000028:3
742 shares@ US$86.520.0048% mcap0.2% of flowCommon StockSEC:0001613801-26-000028:4
900 shares@ US$88.000.0060% mcap0.2% of flowCommon StockSEC:0001613801-26-000028:5
263 shares@ US$88.810.0018% mcap0.1% of flowCommon StockSEC:0001613801-26-000028:6
998 shares@ US$84.130.0063% mcap0.2% of flowCommon StockSEC:0001613801-26-000028:2
3,580 shares@ US$93.140.025% mcap0.9% of flowCommon StockSEC:0001613801-26-000026:0
1,420 shares@ US$93.900.0100% mcap0.3% of flowCommon StockSEC:0001613801-26-000026:1
1,162 shares@ US$89.730.0078% mcap0.3% of flowCommon StockSEC:0001613801-26-000026:2
140 shares@ US$90.600.0010% mcap0.0% of flowCommon StockSEC:0001613801-26-000026:3
592 shares@ US$92.660.0041% mcap0.1% of flowCommon StockSEC:0001613801-26-000026:5
606 shares@ US$91.650.0042% mcap0.1% of flowCommon StockSEC:0001613801-26-000026:4
1,847 shares@ US$91.840.013% mcap0.4% of flowCommon StockSEC:0001613801-26-000024:0
2,564 shares@ US$92.790.018% mcap0.6% of flowCommon StockSEC:0001613801-26-000024:1
589 shares@ US$93.450.0041% mcap0.1% of flowCommon StockSEC:0001613801-26-000024:2
2,107 shares@ US$93.710.015% mcap0.5% of flowCommon StockSEC:0001613801-26-000024:3
393 shares@ US$94.550.0028% mcap0.1% of flowCommon StockSEC:0001613801-26-000024:4
25 of 204 declarations
About Iradimed Corp
IRADIMED CORP. (ticker: IRMD) is a U.S.-based medical device company listed on the NASDAQ market in the United States. The company operates in a highly specialized segment of healthcare equipment: it designs, manufactures, markets, and distributes MRI-compatible medical devices, along with related accessories, disposables, and services. Its business is focused on safety-critical applications in hospitals and care settings where patients must receive infusion therapy and vital-sign monitoring during MRI procedures, an environment in which conventional equipment can pose safety and operational challenges. ([static1.squarespace.com](https://static1.squarespace.com/static/640779294f16ad6e3bf57fc8/t/6781a843facb34455f60e189/1736550467421/IRMD%2BPR%2B-%2BPreliminary%2BQ4%2B2024%2BRevenue%2Bfor%2BJPM%2B%28KLG%2BComments%29-508881756-v2.pdf))
IRADIMED’s roots go back to 1992, when it was originally incorporated in Oklahoma as IRI Development, Inc. The company was later reorganized into a Delaware corporation in April 2014. Its founder, Roger Susi, has a long operating history in MRI patient monitoring; he founded Invivo Research in 1979, where he helped develop the first MRI-compatible patient monitoring system. That historical lineage is important because it shows IRADIMED as a technology company built around decades of domain expertise in MRI-safe patient care. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001325618/000110465926024691/irmd-20251231x10k.htm))
Read moreShow less
The product portfolio is centered on four core offerings for the scanner room: the MRidium 3870 MRI-compatible IV infusion pump system, the MRidium 3860+ MRI-compatible IV infusion pump system, the 3880 MRI-compatible patient vital signs monitoring system, and the 3600 FMD with RALU FMD. The company emphasizes that its pumps are non-magnetic, engineered for use in magnetic fields ranging from 0.2T to 3T, and equipped with clinical features such as drug libraries, alarms, and rechargeable battery operation. Management also states that IRADIMED has no current direct competitor in MRI-compatible IV infusion pumps, supporting a defensible niche position. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001325618/000110465926024691/irmd-20251231x10k.htm))
Commercially, the company sells through a direct U.S. sales force and a network of international distributors. While its legacy market has been MRI departments, IRADIMED is expanding its footprint into intensive care units, emergency rooms, and other critical-care settings to broaden adoption of MRI-compatible devices across the hospital. The company’s headquarters and primary manufacturing operation are now located in Orlando, Florida, in a purpose-built facility of approximately 62,300 square feet that was funded entirely with cash. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001325618/000110465926024691/irmd-20251231x10k.htm))
Recent developments have been constructive. In 2025, IRADIMED introduced the next-generation MRidium 3870 pump, which management says should support growth in 2026 and beyond. The company also increased shareholder returns, raising its regular quarterly dividend to $0.20 per share in February 2026 after declaring a special cash dividend of $0.50 per share in December 2025. In its 2026 outlook, management guided to revenue of $91 million to $96 million, signaling continued demand momentum and operating discipline. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001325618/000110465926024691/irmd-20251231x10k.htm))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
